Digital health tools for rare metabolic disorders show promise but miss holistic care

Glycogen storage diseases are rare inherited metabolic disorders that demand constant, intricate management across a patient's lifetime. They affect how the body processes and stores glucose, with consequences that ripple through multiple organ systems. For people living with these conditions, the stakes are high and the path forward is rarely straightforward. Yet when researchers looked at how digital health technologies are being deployed to help manage these diseases, they found a landscape that is both promising and oddly narrow.

A systematic review of 44 studies involving 662 participants across 17 different GSD subtypes, completed through June 2026, mapped the current state of digital health tools in this space. The findings reveal a field concentrated geographically and clinically in ways that may not serve all patients equally. Nearly half of all research activity is happening in Europe, which means that insights and tools developed there may not translate well to other regions or healthcare systems. More striking still is the clinical focus: 59 percent of the studies examined hepatic subtypes—the forms of GSD that primarily affect the liver—while muscle-related variants received far less attention despite their own complexity and impact on quality of life.

Continuous glucose monitoring emerges as the dominant technology, appearing in 66 percent of the studies reviewed. These devices, which track blood sugar levels in real time, are genuinely useful for managing the metabolic side of these diseases. They give patients and clinicians immediate visibility into glucose patterns and allow for faster intervention when levels drift into dangerous territory. But this glucose-centric approach, while clinically valuable, tells only part of the story of what it means to live with a glycogen storage disease. The research landscape reveals minimal investigation into movement behavior, physical activity patterns, or the psychological and emotional dimensions of managing a rare, lifelong condition.

The review identified five broad categories of how digital health is currently being used in GSD research: evaluating new interventions, enhancing communication between patients and providers, monitoring clinical status, tracking disease patterns across populations, and developing new technologies themselves. Yet within these categories, the gaps are substantial. Behavioral monitoring—how much a person moves, how their activity patterns change, what barriers they face to physical engagement—barely registers in the literature. Psychosocial evaluation, which would capture the mental health burden, social isolation, and quality-of-life dimensions of living with a rare disease, is nearly absent.

This matters because people with glycogen storage diseases face challenges that extend far beyond glucose levels. They navigate dietary restrictions, fatigue, muscle weakness, organ complications, and the psychological weight of managing a condition that few people around them understand. A digital health ecosystem that tracks only glucose is like a weather station that measures temperature but ignores wind, precipitation, and barometric pressure. It captures one dimension of a complex system.

The researchers behind this review argue that the field needs to evolve toward what they call comprehensive digital ecosystems—integrated platforms that would monitor metabolic markers alongside behavioral data and psychosocial indicators. Such systems would need to work across all GSD subtypes, not just the hepatic forms that currently dominate research. They would need to be developed and tested in diverse geographic regions to ensure they actually work for patients in different healthcare contexts. And they would need to be designed with the understanding that managing a rare metabolic disorder is not a technical problem alone; it is a human problem that unfolds across the whole of a person's life.

The path forward requires both expansion and integration. Expansion means bringing muscle subtypes and other underrepresented variants into the research pipeline, and extending digital health development beyond Europe to regions where these diseases also occur but where research infrastructure may be thinner. Integration means building tools that do not just measure glucose but also capture how patients are moving, how they are coping, how their social connections are holding up, and what their lived experience actually looks like day to day. Until that happens, digital health in rare metabolic disease will remain powerful but incomplete.